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Abstract
Background: Blood stream infections (BSI) with Pseudomonas aeruginosa lead to poor clinical outcomes. The
worldwide emergence and spread of metallo-β-lactamase (MBL) producing, often multidrug-resistant organisms
may further aggravate this problem. Our study aimed to investigate the effect of MBL-producing P. aeruginosa
(MBL-PA) and various other resistance phenotypes on clinical outcomes.
Methods: A retrospective cohort study was conducted in three German hospitals. Medical files from 2006 until
2012 were studied, and a number of 113 patients with P. aeruginosa BSI were included. The presence of VIM, IMP
and NDM genes was detected using molecular techniques. Genetic relatedness was assessed through multilocus
sequence typing (MLST). The effect of resistance patterns or MBL production on clinical outcomes was investigated
by using multivariate Cox regression models.
Results: In-hospital mortality was significantly higher in patients with MBL-PA and multidrug-resistant P. aeruginosa.
However, neither BSI with MBL-PA nor BSI with various resistance phenotypes of P. aeruginosa were independently
associated with mortality or length of hospital stay. In multivariate models, the SAPS II score (HR 1.046), appropriate
definitive treatment (HR range 0.25-0.26), and cardiovascular disease (HR range 0.44-0.46) were independent
predictors of mortality. Concomitant infections were associated with an excess length of stay (HR < 1).
Conclusions: Medication with appropriate antimicrobial agents at any time during the course of infection remains
the key for improving clinical outcomes in patients with P. aeruginosa BSI and should be combined with a strict
implementation of routine infection control measures.
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Background
Pseudomonas aeruginosa is an important nosocomial
pathogen [1]. Blood stream infections, primarily ob-
served in immunosuppressed individuals, are associated
with high mortality [2,3]. The worldwide emergence of
multidrug-resistant P. aeruginosa over the course of the
last decades called the reliance on various antimicrobial
agents into question [4-8]. The production of metallo-β-
lactamase (MBLs) which confer resistance to all β-lactams
except aztreonam is a mechanism of increasing clinical
importance, largely driven by the international spread
of MBL-producing organisms [9]. Therapeutic options
against such strains are often severely compromised since
other determinants of resistance tend to be linked to MBL
genes on the same plasmid or integron structure [10,11].
Moreover, MBLs cannot be inhibited by currently ap-
proved β-lactamase inhibitors [12]. Several types of MBLs
have been described, most importantly the IMP-type,
VIM-type, and NDM-type enzymes [9].
Despite the growing body of epidemiological reports
of metallo-β-lactamase-producing P. aeruginosa (MBL-
PA) [8,9,13], more information about the clinical charac-
teristics of MBL-PA infections is urgently needed. Most
notably, the association between MBL-PA infection and
clinical outcomes remains an unresolved issue. In two
studies, a higher frequency of infection and fatal cases
in patients with MBL-PA has been described [14,15].
Zavascki et al. also reported on a higher mortality among
patients with MBL-PA nosocomial infections, but con-
cluded that this result is most likely due to a delayed
administration of appropriate treatment and the severity
of the infections [16].
The aim of this study was to investigate the impact of
MBL-production and different phenotypes of resistance
on mortality and length of hospital stay in patients with
P. aeruginosa blood stream infection and to shed some




The retrospective cohort study was performed from 1st
January 2006 until 31st January 2012 in a 1500-bed tertiary
teaching hospital, a 300-bed trauma center and a 500-bed
district hospital in Tübingen, Germany, and the surround-
ing community. A broad spectrum of medical services is
provided by these hospitals, including various surgical and
medical specialties, pediatric units, dialysis and a maternity
ward. Organ transplantations are performed at the tertiary
teaching hospital. The study is reported pursuant to the
STrengthening the Reporting of OBservational studies in
Epidemiology (STROBE) guidelines [17]. The study has
been approved by the local research ethics committee of
the University of Tübingen (reference number: 035/2012R).
Study design and definitions
Adult patients (≥ 18 years) suffering from a blood
stream infection (BSI) with ≥ 1 blood culture positive for
P. aeruginosa were considered eligible. Patients were ex-
cluded if they were not admitted to the hospital. Hybase
software (Tieto GmbH, Eschborn, Germany) was used to
retrospectively identify eligible patients from the labora-
tory information system. Every patient was included only
once at the time of the first positive blood culture (index
culture).
In-hospital mortality for any cause and length of
hospital stay were the primary outcomes, while exposure
to strains of P. aeruginosa producing an MBL enzyme or
to isolates exhibiting different resistance phenotypes was
the variable of interest. Multidrug-resistant P. aeruginosa
(3/4MDR-PA) was defined as resistant to at least three of
the following antimicrobial agents: piperacillin-tazobactam;
ceftazidime; meropenem; and ciprofloxacin [18]. For the
definition of multidrug resistance we considered anti-
microbial agents which have a bactericidal effect on
P. aeruginosa and can be administered as effective
monotherapy. Thus, aminoglycosides were not a part of
the definition [18]. Intermediately susceptible isolates were
deemed resistant. MBL-PA was defined as MBL-producing
organism regardless of the susceptibility pattern.
Patient files were reviewed by medically trained
personnel. Clinical data obtained included age; sex; site
of infection (primary, secondary, vascular catheter-
related) according to the definition of the International
Sepsis Forum [19]; nosocomial infection (defined as in-
fection that occurred ≥ 48 hours after hospital admis-
sion); baseline diseases; Charlson comorbidity score at
admission [20]; immunosuppression, such as HIV and/or
neutropenia (neutrophil count ≤ 1000 cell/μl) and/or im-
munosuppressive chemotherapy within the previous two
months (anti-cancer drugs and anti-inflammatory mono-
clonal antibodies) and/or receipt of steroids (prednisol-
one ≥ 10 mg/daily or equivalent dose); previous surgery
during hospitalization; and the presence of concomitant
infections with relevant pathogenic organisms other than
P. aeruginosa. The individual physiological condition
was assessed by determining the simplified acute physi-
ology score II (SAPS II) of the index culture day [21]. If
a SAPS II parameter was not available for the index cul-
ture day, it was gained from the time point closest to the
index culture day (± 48 hours).
Appropriate antimicrobial treatment was defined as
systemic administration of at least one antimicrobial agent
to which the isolate was in vitro susceptible. Monotherapy
with aminoglycosides was not considered appropriate des-
pite in vitro susceptibility. Appropriate antimicrobial treat-
ment was categorized in i) appropriate empirical treatment
(AET) which was administered within 24 hours after sam-
ples for blood cultures were drawn, and ii) appropriate
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definitive treatment (ADT) which was administered at any
time after the index culture.
Species identification and phenotypic testing
Species identification was performed through a linear
MALDI-TOF mass spectrometer (AXIMA Assurance,
bioMérieux, Marcy l’Etoile, France, Saramis Database
Version 4.09), supplemented by Vitek 2 system identifi-
cation (bioMérieux, Marcy l’Etoile, France). In vitro bac-
terial susceptibility testing of P. aeruginosa isolates was
performed by use of disk diffusion tests following the
EUCAST guidelines [22-24]. Colistin susceptibility was
interpreted according to the CLSI breakpoints [25]. For
MBL detection, a combined disk test with EDTA was
performed on all isolates as previously described [26].
Briefly, antibiotic disks (Becton Dickinson GmbH, Hei-
delberg, Germany) containing 10 μg meropenem alone
and in combination with 930 μg EDTA were used. An
increase of ≥ 7 mm in zone diameter in the presence of
EDTA compared to the meropenem disk alone was con-
sidered an indication of possible MBL production.
PCR assays and DNA sequencing
P. aeruginosa isolates having a reduced meropenem zone
size (defined as < 24 mm) and/or being positive in the
EDTA combined disk test were further investigated for
the presence of MBL genes [26]. Whole cell DNA was
used as a template in PCR assays. For the simultaneous
detection of blaVIM and blaIMP genes, a multiplex PCR
amplification was performed according to a protocol de-
scribed elsewhere [26]. The entire VIM and IMP genes
were sequenced using the primer pairs IMP-A–IMP-B
or VIM2004A-VIM2004B in combination with the class
1 integron primer pair 5CS and 3CS or alternatively
VIM-2SQR [26,27]. Isolates negative for VIM and IMP
genes that exhibited reduced meropenem and ceftazi-
dime zone sizes (defined as < 24 mm and < 16 mm, re-
spectively) were further investigated for the presence
of NDM and class A carbapenemase (KPC and GES)
genes at the National Reference Laboratory for Multidrug-
resistant Gram-negative Bacteria (Bochum, Germany) by
using molecular detection techniques.
Multilocus sequence typing (MLST)
MLST was performed on the 3/4MDR-PA including all
MBL-PA in accord with the instructions on the P. aeruginosa
MLST web site (http://pubmlst.org/paeruginosa/). In-
ternal fragments of seven housekeeping genes (acsA, aroE,
guaA, mutL, nuoD, ppsA and trpE) were amplified and
subsequently sequenced to determine the sequence type.
Statistical analysis
D’Agostino’s K-squared test was used to check continu-
ous variables for normality. The Student t-test was used
for comparison when data were normally distributed. The
Wilcoxon rank sum test was performed when transform-
ation of variables could not achieve a normal distribution
of values. A chi-squared test or–when appropriate–the
Fisher’s exact test were employed to compare differences
in proportions.
Cox regression was used to model the relationship be-
tween the exposure (blood stream infection with MBL-
PA or a certain resistance type of P. aeruginosa) and the
two outcomes (in-hospital mortality and length of stay)
by calculating the hazard ratio for death and the hazard
ratio for discharge (dead or alive). Exposed patients were
compared with the rest of the cohort. To determine the
effect on morbidity, the length of stay (LOS) was consid-
ered as failure variable. A hazard ratio of discharge <1
indicates a smaller hazard of being discharged and there-
fore an excess of stay adjusted for the length of stay be-
fore the index day (time-adjusted model) and additional
confounders (fully-adjusted model) [28]. Hypothesis test-
ing was performed by using the likelihood ratio test.
Model identification for multivariate analysis was ac-
complished as described elsewhere [29]. Briefly, any vari-
able with a P-value of < 0.2 in univariate analysis was
incorporated in multivariate models, wherein only vari-
ables with a P-value of ≤ 0.1 were retained. Excluded var-
iables were subsequently tested for confounding by
adding them one at a time to the identified model. In
case of substantial confounding (defined as a change in
the models’ coefficients greater than 10%) they were in-
cluded into the final model. The exposure of interest
was always retained in the model, regardless of the p-
value. Potential interactions were examined through the
likelihood ratio test. The proportional hazards assump-
tion was verified on the basis of Schoenfeld residuals.
All analyses were carried out by using Stata version
12.0 (Stat Corp., College Station, TX, USA). A P-value <
0.05 (two-sided) was deemed significant.
Results
MBL detection and susceptibility profiles
Over the course of the six year study a total of 6064 pa-
tients with bacterial BSI were identified. Of these, 120
patients (2%) had a PA-BSI. Three patients were ex-
cluded because they were not admitted to the hospital.
Of the remaining 117 study entrants, four patients were
excluded from the analysis because clinically relevant
data were missing. The remaining 113 patients were
analyzed.
A number of 34 isolates met the criteria for a possible
MBL production and were subsequently tested for the
presence of MBL genes. Eighteen isolates (15.9%) that pos-
sessed a gene for a metallo-β-lactamase were detected.
Four isolates were positive for VIM-2 (3.5%) and 14 iso-
lates for IMP-8 (12.4%). The results of the susceptibility
Willmann et al. BMC Infectious Diseases 2013, 13:515 Page 3 of 9
http://www.biomedcentral.com/1471-2334/13/515
testing are shown in Table 1. All MBL-PA were susceptible
to colistin but resistant to all other tested antimicrobials.
Non-MBL-PA remained susceptible to a number of anti-
microbial agents, particularly to ceftazidime (95%), amika-
cin (96%) and meropenem (85%). All P. aeruginosa isolates
were susceptible to colistin.
Study population characteristics
Table 2 presents the basic characteristics of the study co-
hort. The median age was 64 years (IQR, 53-74 years)
with 48% over 65 years. Male gender was predominant
(63%). Frequent comorbidities were cardiovascular dis-
eases (58%), diabetes (33%) and hematological cancer
(32%). The most common sources of infection were the
respiratory and urinary tract (19% and 16%, respectively).
The source of infection was not identifiable in 44% of
cases. The mean time to effective treatment was 1.05 days
in our cohort.
The in-hospital mortality was 38%. Differences in
baseline characteristics between the two exposure
groups MBL-PA and 3/4MDR-PA are shown in Table 3.
Patients infected with a MBL-PA had a higher mortality
than those with a Non-MBL-PA (61% vs. 34%, P = 0.03).
A BSI with a 3/4MDR-PA resulted in a higher mortality
as well (63% vs. 30%, P = 0.002). Interestingly, while pa-
tients with MBL-PA BSI overall had a higher SAPSII score
(39.5 vs. 32.0, P = 0.002), there was merely a tendency to-
wards a difference in the administration of definitive ap-
propriate treatment in comparison to the Non-MBL-PA
group. The opposite seemed to be true for patients with
3/4MDR-PA BSI: No significant difference in SAPSII was
observed, but the number receiving appropriate definitive
treatment was significantly lower (70% vs. 90%, P = 0.03).
Patients infected with MBL-PA or 3/4MDR-PA were more
frequently neutropenic (p < 0.001).
Clinical outcomes
Table 4 shows the results of the univariate analysis.
While BSIs with 3/4MDR-PA and P. aeruginosa strains
resistant to meropenem (MEM-resistant PA) were sig-
nificantly associated with mortality (HR 1.98, P = 0.03,
and HR 1.98, P = 0.03, respectively), this relationship was
less conclusive for MBL-PA (HR 1.83, P = 0.1) and cef-
tazidime resistant P. aeruginosa (CAZ-resistant PA, HR
1.88, P = 0.06). Ciprofloxacin resistant P. aeruginosa
(CIP-resistant PA) and piperacillin-tazobactam resistant
P. aeruginosa (TZP-resistant PA) showed no significant
impact on mortality (P = 0.43 and 0.28, respectively). Of
note, appropriate empirical treatment turned out not to
Table 1 Susceptibility profile of the 113 Pseudomonas
aeruginosa clinical isolates
Antimicrobial agent MBL (n = 18),
susceptible
isolates (%)











Table 2 Basic characteristics of 113 adult patients with
Pseudomonas aeruginosa BSI
Parameter Patients n (%)
Basic parameter
Age > 65 years 54 (48)
Male sex 71 (63)
Nosocomial infection 66 (58)




Hematological cancer 36 (32)
Cardiovascular disease 66 (58)
Pulmonary disease 11 (10)
Neurologic disease 24 (21)
Renal disease 11 (10)
Neutropenia 38 (34)
Origin of bacteremia
Unknown (primary BSI) 50 (44)
Secondary BSI 55 (49)
Respiratory tract 21 (19)
Urinary tract 18 (16)
Intra-Abdominal 5 (4)
Surgical Site 1 (1)
Non-surgical site 10 (9)




MEM-resistant PA 32 (28)
CAZ-resistant PA 23 (20)
CIP-resistant PA 39 (35)
TZP-resistant PA 34 (30)
BSI, Bloodstream infection; HIV, Human immunodeficiency virus infection;
VC BSI, vascular catheter-related blood stream infection; MBL-PA, metallo-
β-lactamase producing Pseudomonas aeruginosa; 3/4MDR-PA, 3/4MDR-
Pseudomonas aeruginosa; PA, Pseudomonas aeruginosa; MEM, Meropenem;
CAZ, Ceftazidime; CIP, Ciprofloxacin; TZP, Piperacillin-tazobactam.
Willmann et al. BMC Infectious Diseases 2013, 13:515 Page 4 of 9
http://www.biomedcentral.com/1471-2334/13/515
be a predictor of mortality (P = 0.52). Neither MBL-PA
nor 3/4MDR-PA or P. aeruginosa strains with a resist-
ance to certain antimicrobial agents (MEM, CAZ, CIP,
TZP) had an effect on length of stay (LOS) when the en-
tire cohort was investigated. Including only the survivors
in the analysis (n = 70), a weak association between MBL-
PA, 3/4MDR-PA and LOS became apparent (P = 0.08 and
P = 0.06, respectively), indicating an extended LOS for
those patients infected with the multidrug-resistant strains
(HR 0.49 and 0.55, respectively).
In multivariate models, the SAPS II score (HR 1.046),
cardiovascular disease (HR range 0.44-0.46) and appro-
priate definitive treatment (HR range 0.25-0.26) were
significantly associated with mortality. After adjusting
for these confounders, neither MBL-PA nor 3/4MDR-PA
remained associated with mortality (Table 5). Also, re-
sistance to either meropenem, ceftazidime, ciprofloxa-
cin or piperacillin-tazobactam on its own was not
associated with mortality (data not shown). Further-
more, we did not observe a significant influence of
MBL-PA or 3/4MDR-PA on LOS in the fully adjusted
models (Table 5). Instead, the presence of concomi-
tant infections was a significant predictor of discharge
in all models (HR < 1).
Multi locus sequence typing results
To investigate whether the results could be influenced
by the genetic relatedness of our strains, we performed
molecular typing of all 27 isolates exhibiting a multidrug-
resistant phenotype (3/4MDR). Ten different sequence
types were observed (data not shown). Of note, the four-
teen IMP-8 producing isolates belonged to the sequence
type 308. VIM-2 producing isolates belonged to the
sequence types 233 (n = 3) and 395 (n = 1). Non-3/4MDR-
PA (n = 86) showed a wide variety of resistance pheno-
types and were therefore considered to have a low degree
of genetic relatedness.
Discussion
Despite the extensive spread of MBL-producing organ-
isms, the influence of such pathogens on clinical out-
comes has not been comprehensively assessed. The
present study showed that MBL-PA BSI results in a
higher in-hospital mortality than BSI with Non-MBL-
PA. These results are in line with earlier reports [14-16].
However, BSI with MBL-PA did not turn out to be an
independent predictor of mortality. The higher mortality
in the MBL-PA group seemed mainly mediated by the se-
verity of the underlying diseases, as previously reported by
Table 3 Baseline characteristics, comorbidities and treatment parameters of different multidrug-resistant Pseudomonas
aeruginosa
Parameter MBL (n = 18) Non-MBL (n = 95) P-value 3/4MDR (n = 27) Non-3/4MDR (n = 86) P-value
Basic parameters
Age, years* 60 (53-64) 67 (52-74) 0.16 59 (48-64) 68.5 (54-75) 0.01
Male sex (%) 11 (61) 60 (63) 0.87 17 (63) 54 (63) 0.99
Fatal outcome (%) 11 (61) 32 (34) 0.03 17 (63) 26 (30) 0.002
Length of stay, days* 23 (20-45) 15 (8-41) 0.03 23 (13-45) 14.5 (7-41) 0.03
Comorbid conditions
Immune suppression (%) 18 (100) 76 (80) 0.04 27 (100) 67 (78) 0.006
Neutropenia (%) 15 (83) 23 (24) <0.001 17 (63) 21 (24) <0.001
Cardiovascular disease (%) 7 (39) 59 (62) 0.07 11 (41) 55 (64) 0.03
Diabetes (%) 5 (28) 32 (34) 0.62 7 (26) 30 (35) 0.39
Pulmonary disease (%) 1 (6) 10 (11) 1 1 (4) 10 (12) 0.46
Neurological disease (%) 2 (11) 22 (23) 0.35 6 (22) 18 (21) 0.89
Renal disease (%) 0 (0) 11 (12) 0.21 1 (4) 10 (12) 0.46
Haematological cancer (%) 17 (94) 19 (20) <0.001 20 (74) 16 (19) <0.001
Charlson Comorbidity Score* 2 (2-3) 3 (1-5) 0.86 2 (2-3) 3 (2-5) 0.27
Patients clinical record
SAPS II* 39.5 (36-44) 32 (23-41) 0.002 37 (28-43) 32 (24-41) 0.57
AET (%) 8 (44) 66 (70) 0.04 11 (41) 63 (73) 0.002
ADT (%) 13 (72) 83 (87) 0.14 19 (70) 77 (90) 0.03
*Median (interquartile range).
MBL-PA, metallo-β-lactamase producing Pseudomonas aeruginosa; 3/4MDR-PA, 3/4MDR-Pseudomonas aeruginosa; SAPS II, Simplified Acute Physiology Score II;
AET, appropriate empirical treatment; ADT, appropriate definitive treatment.
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Zavascki and colleagues in patients with various noso-
comial infections [16]. While the administration of ap-
propriate definitive treatment had independently a strong
protective effect (HR range 0.25-0.26), there was only a
weak tendency that patients with MBL-PA BSI were less
likely to have received sufficient therapy. After the emer-
gence of the first MBL-PA isolates, colistin (colistimethate
sodium) was added to the empirical therapeutic regime
when a BSI with P. aeruginosa was suspected. MBL-PA
isolates were resistant to all antimicrobial agents except
for colistin. In fact, colistin was intravenously adminis-
tered to 13 of 18 patients with MBL-PA BSI (72%), and
these patients were considered to have received appropri-
ate therapy. It can be speculated that colistin has im-
proved the outcome of these patients in our setting. This
hypothesis is supported by the fact that the treatment
Table 4 Univariate analysis: Hazard ratios for deaths and discharge (dead or alive) in patients with Pseudomonas
aeruginosa BSI
Exposure Hazard ratio for
deaths (95% CI)
P-value Hazard ratio for
discharge–time
adjusted (95% CI)
P-value Hazard ratio for
discharge–time adjusted
(95% CI) only survivors (n = 70)
P-value
Basic parameter
Male sex 1.02 (0.55-1.88) 0.95 1.14 (0.77-1.68) 0.5 1.28 (0.77-2.12) 0.32
Age, years 1.0073 (0.9889-1.0261)* 0.43 1.0164 (1.0039-1.0291)* 0.007 1.0155 (0.9938-1.033)* 0.07
Nosocomial infection 2.14 (1.05-4.27) 0.03 0.67 (0.42-1.07) 0.1 0.52 (0.28-0.97) 0.04
Origin of bacteremia
Unknown (primary BSI) 1.07 (0.57-2) 0.83 1.85 (1.24-2.75) 0.003 2.22 (1.32-3.73) 0.003
Secondary BSI 1.25 (0.67-2.31) 0.47 0.79 (0.53-1.16) 0.24 0.76 (0.46-1.25) 0.29
VC BSI 0.22 (0.03-1.66) 0.06 0.39 (0.18-0.85) 0.008 0.37 (0.15-0.89) 0.01
Comorbid conditions
Immune suppression 2.31 (0.71-7.55) 0.12 0.54 (0.31-0.94) 0.04 0.5 (0.26-0.96) 0.04
Haematological cancer 1.23 (0.67-2.28) 0.5 0.61 (0.39-0.93) 0.02 0.5 (0.27-0.91) 0.02
Chemotherapy 0.83 (0.45-1.56) 0.58 0.62 (0.41-0.94) 0.02 0.6 (0.35-1.03) 0.06
Cardiovascular disease 0.65 (0.36-1.2) 0.18 0.77 (0.52-1.14) 0.2 0.83 (0.49-1.38) 0.48
Diabetes 1.43 (0.77-2.65) 0.25 0.78 (0.51-1.19) 0.25 0.55 (0.31-0.99) 0.04
Charlson Comorbidity Score 0.96 (0.83-1.11)* 0.66 1 (0.92-1.1)* 0.83 1.01 (0.9-1.13)* 0.77
Patients clinical record
SAPS II 1.0375 (1.0184-1.057)* <0.001 0.9961 (0.9828-1.0097)* 0.58 0.974 (0.9557-0.9926)* 0.005
Neutropenia 1.41 (0.77-2.58) 0.27 0.62 (0.4-0.94)† 0.02 0.43 (0.23-0.79) 0.004
Chemotherapy 0.83 (0.45-1.56) 0.58 0.62 (0.41-0.94) 0.02 0.6 (0.35-1.03) 0.06
Steroids 1.82 (0.86-3.84) 0.1 0.46 (0.3-0.7) <0.001 0.3 (0.17-0.54) <0.001
Concomitant infections 1.22 (0.56-2.71) 0.59 0.27 (0.16-0.44) <0.001 0.23 (0.11-0.46) <0.001
Recent surgery 0.65 (0.34-1.22) 0.18 0.54 (0.35-0.81) 0.003 0.47 (0.27-0.82) 0.007
AET 0.81 (0.44-1.5) 0.52 0.89 (0.59-1.34) 0.6 0.9 (0.53-1.51) 0.7
ADT 0.33 (0.16-0.68) 0.007 0.44 (0.25-0.77) 0.008 0.4 (0.17-0.92) 0.052
Pathogen exposure
MBL-PA 1.83 (0.92-3.64) 0.1 0.75 (0.44-1.27) 0.27 0.49 (0.21-1.17) 0.08
3/4MDR-PA 1.98 (1.07-3.67) 0.03 0.76 (0.49-1.19) 0.23 0.55 (0.25-1.07) 0.06
MEM-resistant PA 1.98 (1.08-3.62) 0.03 0.85 (0.55-1.3) 0.45 0.64 (0.33-1.23) 0.17
CAZ-resistant PA 1.88 (0.99-3.57) 0.06 0.72 (0.45-1.16) 0.17 0.53 (0.25-1.15) 0.09
CIP-resistant PA 1.27 (0.69-2.34) 0.43 0.93 (0.62-1.39) 0.73 0.78 (0.45-1.34) 0.38
TZP-resistant PA 1.41 (0.76-2.61) 0.28 0.78 (0.52-1.19) 0.26 0.68 (0.37-1.23) 0.2
†Proportional hazard assumption not fulfilled for this parameter.
*Per 1 unit increase.
95% CI, 95% Confidence interval; BSI, blood stream infection; VC BSI, vascular catheter-related blood stream infection; SAPS II, Simplified Acute Physiology Score;
AET, appropriate empirical treatment; ADT, appropriate definitive treatment; MBL-PA, metallo-β-lactamase producing Pseudomonas aeruginosa; 3/4MDR-PA,
3/4MDR-Pseudomonas aeruginosa; PA, Pseudomonas aeruginosa; MEM, Meropenem; CAZ, Ceftazidime; CIP, Ciprofloxacin; TZP, Piperacillin-tazobactam.
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variable for definitive therapy proved to be strongly protect-
ive when regarding colistin as appropriate treatment in the
multivariate models. However, our study was not designed
to resolve this issue. And despite the growing evidence for
the therapeutic benefit of intravenous colistin in adult
patients infected with multidrug-resistant P. aeruginosa
[30-32], prospective and randomized control trials are re-
quired to prove its efficacy and safety.
Different phenotypes of resistance of P. aeruginosa in
BSI did not prove to be independent predictors of mor-
tality, either. In the case of 3/4MDR-PA, the observed
difference in mortality compared to Non-3/4MDR-PA
(63% vs 30%, P = 0.002, Table 3) appeared to be due to
the lower chance of patients with 3/4MDR-PA BSI to
have received appropriate definitive treatment. This
emphasizes the importance of reevaluating the initial
therapeutic regimes in a hospital setting with a relevant
incidence of multidrug-resistant P. aeruginosa. It also
stresses the importance of susceptibility testing results
from the associated microbiology laboratories and the
need to effectively and appropriately adjust empirical
treatments where necessary. Whether multidrug-resistant
phenotypes of P. aeruginosa have an intrinsic influence on
the risk of a lethal outcome is still controversial. While
some studies revealed infection with multidrug-resistant
P. aeruginosa to be an independent predictor of mortality
[3,33,34] others have not observed such a connection
[35,36]. The reasons for this heterogeneity are unknown.
However, one possibility is that not all of these studies
performed molecular genotyping, and their results could
have been influenced by the presence of just a few domin-
ant strains, possibly in possession of virulence factors that
could have contributed to worse clinical outcomes [37].
These or similar circumstances may have led to confound-
ing effects. Although we did not perform molecular typing
for all isolates, the identification of 10 different MLST se-
quence types among the multidrug-resistant phenotypes
(3/4MDR-PA) in our study makes such a confounding less
likely, with the exception of the 18 MBL-PA isolates which
belong to three different strains. These strains circulated
in only a few wards at the tertiary teaching hospital, sug-
gesting that transmission within the hospital is still a
major factor for the spread of MBL-PA. Another reason
for our observations might be the limitation in study
power. Since we needed to get by with less than 10 out-
come events per variable in our multivariate models, we
may have been incapable of detecting a minor effect of
MBL producers or resistant phenotypes on mortality.
Nevertheless, a relevant influence on mortality is unlikely
to have been overlooked. Larger-scaled, multicenter stud-
ies are still required to investigate this issue and to
generalize results to other settings with confidence.
The absence of a significant relation between an appro-
priate empirical treatment (within 24 hours) and mortality
is another interesting finding. Lodise and colleagues noted
that the risk of a fatal outcome rises in patients with
P. aeruginosa BSI once the delay in receiving appropriate
treatment exceeded 52 hours [36]. However, their study
did not provide information about the probable origin of
infection. This might be an important point since inter-
ventions like abolition of urinary obstructions and removal
of catheters are the mainstay of therapy in blood stream
infections with the urinary tract or a vascular catheter as
probable origins of infection, leaving prompt antimicrobial
treatment no more than a secondary role in the clinical
management. This subpopulation of our patients (origin
of infection: 16% urinary tract and 7% vascular catheter-
related, Table 1) may have influenced the results in the ob-
served direction. It must be noted that this proportion
may be an underestimation due to our study’s limitation
as a retrospective investigation. However, we excluded pa-
tients among whom vital clinical information was missing
(4 of 120 patients) and are thus confident that the data ac-
curately represents the real situation to a high degree.
In addition, we investigated whether MBL production
or resistance phenotypes were associated with the length
of stay. BSI with a MBL producer or resistant phenotype
did not prolong the LOS, while the presence of con-
comitant infections besides a PA-BSI did so (HR < 1, all
models). In fully adjusted models wherein only survivors
Table 5 Multivariate analysis: Hazard ratios for deaths and discharge (dead or alive)
Parameter Hazard ratio for
deaths (95% CI)
P-value Hazard ratio for
discharge–fully
adjusted (95% CI)
P-value Hazard ratio for
discharge–fully adjusted
(95% CI) only survivors (n = 70)
P-value
MBL-PA 0.98 (0.45-2.1)a 0.97 1.28 (0.63-2.58)c 0.49 1.53 (0.53-4.45)e 0.44
3/4MDR-PA 1.37 (0.68-2.72)b 0.37 1.24 (0.69-2.21)d 0.46 0.75 (0.31-1.83)f 0.53
aSignificant in the same model: SAPS II (HR 1.046, P < 0.001), cardiovascular disease (HR 0.44, P = 0.015) and ADT (HR 0.25, P = 0.002).
bSignificant in the same model: SAPS II (HR 1.046, P < 0.001), cardiovascular disease (HR 0.46, P = 0.025) and ADT (HR 0.26, P = 0.003).
cSignificant in the same model: Concomitant infection (HR 0.3, P < 0.001), ADT (HR 0.39, P = 0.004).
dSignificant in the same model: Concomitant infection (HR 0.27, P < 0.001), ADT (HR 0.4, P = 0.007).
eSignificant in the same model: Concomitant infection (HR 0.32, P = 0.002), vascular catheter-related BSI (HR 0.41, P = 0.04), nosocomial infection
(HR 0.44, P = 0.04).
fSignificant in the same model: Concomitant infection (HR 0.32, P = 0.002), neutropenia (HR 0.39, P = 0.006), nosocomial infection (HR 0.37, P = 0.004),
ADT (HR 0.25, P = 0.008).
95% CI, 95% Confidence interval; MBL-PA, metallo-β-lactamase producing Pseudomonas aeruginosa; 3/4MDR-PA, 3/4MDR-Pseudomonas aeruginosa; SAPS II,
Simplified Acute Physiology Score; ADT, appropriate definitive treatment.
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were included, nosocomial infections were also signifi-
cantly associated with a prolonged stay. These results in-
dicate that any concomitant infection should be avoided
to reduce additional morbidity and hospital costs, lead-
ing to the demand for strict routine infection control
measures.
Conclusions
The administration of appropriate definitive treatment
in patients with PA-BSI, even when delayed, remains the
backbone for improving clinical outcomes and should be
combined with routine infection control measures to
further reduce morbidity and costs. The pattern of re-
sistance within a hospital should be continuously moni-
tored for a rapid detection of changes and consecutive
adjustment of empirical treatment regimes.
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